CA
NZ
UK
AU
IND
US
ENvue Medical disclosed a board reshuffle on July 14, 2026, with two longtime members exiting and three individuals stepping into governance roles. The company emphasized that the departures were not driven by any dispute over corporate direction.
American Well Corp (NYSE: AMWL) adjusted its board structure this month, reappointing director Stephen Schlegel to align with exchange requirements. The change follows a resignation and reclassification to ensure balanced representation across the company’s three director classes.
Anika Therapeutics (NASDAQ: ANIK) has finalized a key financing move, extending its revolving credit facility with Bank of America to support long-term operations. The amended agreement provides immediate access to capital while offering flexibility for future growth in the orthopedic and regenerative medicine sectors.
Atrium Therapeutics, Inc. (NASDAQ: RNA) disclosed that its Investigational New Drug filing has been cleared, clearing the path for its upcoming Phase 1/2 study of ATR 1072. The trial aims to address the genetic disorder known as PRKAG2 syndrome, a condition with limited therapeutic …
Two of the healthcare sector’s most prominent companies, Abbott Labs and Pfizer, are managing distinct challenges that have influenced their stock performance. Abbott Labs has experienced a notable decline this year, while Pfizer has contended with shifting demand for some of its key products. …
Alamar Biosciences (ALMR) saw its share price climb sharply after announcing that its NULISA platform, aimed at detecting disease biomarkers, was spotlighted across a wide slate of scientific presentations at the Alzheimer’s Association International Conference.
Valion Bio, Inc. (NASDAQ: VBIO) delivered a corporate press release on July 14, 2026 outlining a new business update. The announcement emphasizes management’s current expectations and the inherent uncertainties that could influence future outcomes.
Genprex (NASDAQ: GNPX) will implement a 1:22 reverse stock split at market open on July 16, 2026. The move consolidates every 22 shares of common stock into one share, reducing the total outstanding from 11,108,577 to approximately 504,936. The par value of $0.001 per …
A hedge fund’s strong quarterly performance has brought AnaptysBio into focus, illustrating the high-stakes nature of biotech investing. The firm’s shares have seen notable appreciation as it transitions to a royalty-based business model, a strategy that has gained traction among clinical-stage biotechs seeking to …
Immunic Inc. (NASDAQ: IMUX) provided new insights into its lead asset, vidofludimus calcium, which targets progressive multiple sclerosis. The July 14, 2026, presentation positions the therapy as a key focus for the company’s neurology pipeline, addressing a segment of the disease with limited treatment …
Please wait processing your request...